On August 20, 2026, Knight Therapeutics Inc., a pharmaceutical company operating in Canada and Latin America, announced the introduction of WYNZORA®, a new topical treatment for psoriasis vulgaris. This cream combines two active ingredients, calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a potent corticosteroid, which work together to reduce inflammation and manage the symptoms of psoriasis.
WYNZORA® is approved for use among adults and adolescents aged 12 and older. As a common skin condition, psoriasis vulgaris affects a significant portion of the population, and new treatment options are essential for improving the management of the disease. The launch of WYNZORA® represents an advancement in the therapeutic options available for patients in Canada who are dealing with this condition.
Knight Therapeutics continues to expand its portfolio with medications that address unmet medical needs in various therapeutic areas. The company aims to provide innovative solutions for patients and healthcare providers, ensuring access to effective treatments across Canada.
Analyzed Canadian Outlets (1)
1 headline